Benefits
Supports Bone Mineral Density
A 2012 systematic review and meta-analysis of soy isoflavone supplement trials in women reported increases in bone mineral density and decreases in urinary deoxypyridinoline, a marker of bone breakdown, with larger effects in postmenopausal women and at doses above 75 mg/day. Important caveat: those trials tested whole soy isoflavone mixtures, not daidzein on its own, so the finding belongs to soy isoflavones generally rather than to daidzein specifically.
Hot Flashes: The Evidence Is Mostly Negative
The largest look at this question, a 2013 Cochrane review of 43 randomised trials in 4,364 peri- and postmenopausal women, concluded there is no conclusive evidence that phytoestrogen supplements reduce the frequency or severity of hot flushes or night sweats. The one encouraging signal in that review came from extracts high in genistein above 30 mg/day, and genistein is a different isoflavone from daidzein. Testing daidzein directly, a 6-month, double-blind, placebo-controlled trial in 270 equol-producing Chinese postmenopausal women found no significant difference between purified daidzein, whole soy and placebo. A smaller pilot trial in 130 women with at least five moderate-to-severe hot flushes a day did find lower hot flush intensity, but only at the highest doses (100 to 200 mg daily) taken two to three times a day, with more benefit at night.
Equol Producer Phenotype Matters
Daidzein only becomes the more active compound equol if your gut bacteria can make the conversion, and only about 40% of people can, with lower rates in Western populations and higher rates in Asian ones. Equol binds the beta estrogen receptor more strongly, and this is probably why studies of daidzein disagree with each other so much. It is not a guarantee of benefit, though: the 6-month trial in 270 women who were all confirmed equol producers still found no significant effect on menopausal symptoms compared with placebo.
Antioxidant Phytoestrogen
In laboratory experiments, daidzein neutralises free radicals and changes the activity of antioxidant enzymes. This is laboratory work only. None of the human studies cited on this page measured antioxidant status or heart-related outcomes, so nothing here should be read as a proven benefit for your heart.
Why Researchers Keep Studying Daidzein
Daidzein attaches more readily to the beta type of estrogen receptor, which is found in bone, brain and some lining tissues. That is the reason researchers keep testing it in women's health. It is a rationale for the research, not a result: the human trials cited here measured hot flushes and bone markers, and none of them tested brain or other tissue outcomes.
Mechanism of action
Estrogen Receptor Beta Binding
Daidzein binds ERβ with greater affinity than ERα, producing tissue-selective phytoestrogenic activity. This receptor profile distinguishes daidzein from estradiol and may explain mixed agonist/antagonist effects across tissues.
Equol Conversion by Gut Bacteria
Specific gut microbes (Slackia, Adlercreutzia, Eggerthella spp.) reduce daidzein to S-equol, a metabolite with stronger ERβ binding and longer half-life. Producer status is largely stable in adulthood and is a major source of inter-individual variability.
Bone Remodeling Modulation
Daidzein and S-equol attenuate osteoclast activity and support osteoblast function in laboratory models, which is a possible explanation for the drop in bone-breakdown markers seen in trials of soy isoflavone mixtures. These are laboratory models, not proof of the same effect in people taking daidzein alone.
Tyrosine Kinase Inhibition
Like genistein, daidzein has weak tyrosine kinase inhibitory activity, which may contribute to its broader effects on cellular signaling pathways beyond estrogen receptors.
Clinical trials
Systematic review and meta-analysis of randomized trials of soy isoflavone supplementation on bone mineral density and bone resorption markers in women.
Aggregated trials in pre- and postmenopausal women.
Soy isoflavone supplementation was linked to increases in bone mineral density and decreases in urinary deoxypyridinoline (a marker of bone breakdown), with greater effects in postmenopausal women and at doses above 75 mg/day of total isoflavones. This review pooled trials of soy isoflavone mixtures, not daidzein on its own, so the result cannot be credited to daidzein specifically. It is also the only bone evidence cited on this page.
Cochrane systematic review of 43 randomized trials (over 4,300 participants) evaluating phytoestrogen supplements including soy isoflavone preparations for hot flashes and night sweats in peri- and postmenopausal women.
Peri- and postmenopausal women with vasomotor symptoms.
The authors concluded there is no conclusive evidence that phytoestrogen supplements reduce the frequency or severity of hot flushes or night sweats in peri- or postmenopausal women. That is a negative result for this class of supplement. The one exception the authors flagged for further study was extracts high in genistein above 30 mg/day, based on four trials that were not pooled statistically. Genistein is a different isoflavone from daidzein, so that signal does not belong to this ingredient. Highlights heterogeneity in formulation, dose, and individual response.
6-month, parallel-group, double-blind, randomized, placebo-controlled trial of whole soy flour, purified daidzein (63 mg/day), or placebo in equol-producing Chinese postmenopausal women with prehypertension. Outcomes: menopausal symptom scales.
270 equol-producing Chinese postmenopausal women enrolled, 253 completing.
There was no significant difference between whole soy, purified daidzein and placebo on menopausal symptoms over 6 months. This is the most direct test of daidzein itself on this page, and it was run in the population most likely to respond, women who were confirmed equol producers. A null result in the best-case group is strong evidence against a meaningful symptom benefit, and being an equol producer clearly does not guarantee one.